R&D at other companies
Other financials
Where this comes from
Reported directly by Protagonist Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Protagonist Therapeutics's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Protagonist Therapeutics's R&D?
- Protagonist Therapeutics (PTGX) reported R&D of $46.74M in Q1 2026.
- How has Protagonist Therapeutics's R&D changed year-over-year?
- Protagonist Therapeutics's R&D increased by 30.2% year-over-year, from $35.89M to $46.74M.
- What is the long-term trend for Protagonist Therapeutics's R&D?
- Over 4 years (2021 to 2025), Protagonist Therapeutics's R&D has grown at a 6.0% compound annual growth rate (CAGR), from $126.01M to $159.29M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.